PIK3CD and melanoma: We evaluated the activity of individual or pan isoform inhibitors of PI3K and/or mTOR alone or in combination with selumetinib or vemurafenib in the cell line panel to investigate if inhibition of PI3K/mTOR signaling could enhance the antitumor activity of selumetinib or vemurafenib in BRAF-mutant melanoma.